These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 29740710)

  • 41. Pituitary adenylate cyclase-activating polypeptide directly stimulates LH and FSH secretion by human pituitary gonadotrophinomas.
    Petersen B; Buchfelder M; Fahlbusch R; Adams EF
    Exp Clin Endocrinol Diabetes; 1996; 104(3):250-5. PubMed ID: 8817243
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Is Involved in Adult Mouse Hippocampal Neurogenesis After Stroke.
    Matsumoto M; Nakamachi T; Watanabe J; Sugiyama K; Ohtaki H; Murai N; Sasaki S; Xu Z; Hashimoto H; Seki T; Miyazaki A; Shioda S
    J Mol Neurosci; 2016 Jun; 59(2):270-9. PubMed ID: 26910758
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of pituitary adenylate cyclase activating polypeptide and its type I receptor mRNAs in human placenta.
    Koh PO; Won CK; Noh HS; Cho GJ; Choi WS
    J Vet Sci; 2005 Mar; 6(1):1-5. PubMed ID: 15785117
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21.
    Robberecht P; Gourlet P; De Neef P; Woussen-Colle MC; Vandermeers-Piret MC; Vandermeers A; Christophe J
    Mol Pharmacol; 1992 Aug; 42(2):347-55. PubMed ID: 1325033
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Progesterone receptor activation mediates LH-induced type-I pituitary adenylate cyclase activating polypeptide receptor (PAC(1)) gene expression in rat granulosa cells.
    Ko C; Park-Sarge OK
    Biochem Biophys Res Commun; 2000 Oct; 277(1):270-9. PubMed ID: 11027674
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evidence for the presence of receptors for pituitary adenylate cyclase-activating polypeptide in the neurohypophysis that are positively coupled to cyclic AMP formation and neurohypophyseal hormone secretion.
    Lutz-Bucher B; Monnier D; Koch B
    Neuroendocrinology; 1996 Aug; 64(2):153-61. PubMed ID: 8857610
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulation of growth hormone release in common carp pituitary cells by pituitary adenylate cyclase-activating polypeptide: signal transduction involves cAMP- and calcium-dependent mechanisms.
    Xiao D; Chu MM; Lee EK; Lin HR; Wong AO
    Neuroendocrinology; 2002 Nov; 76(5):325-38. PubMed ID: 12457043
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors in the brain.
    Shioda S
    Kaibogaku Zasshi; 2000 Dec; 75(6):487-507. PubMed ID: 11197592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The vasoactive peptide maxadilan from sand fly saliva inhibits TNF-alpha and induces IL-6 by mouse macrophages through interaction with the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor.
    Soares MB; Titus RG; Shoemaker CB; David JR; Bozza M
    J Immunol; 1998 Feb; 160(4):1811-6. PubMed ID: 9469441
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond.
    Russo AF; Hay DL
    Physiol Rev; 2023 Apr; 103(2):1565-1644. PubMed ID: 36454715
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cluster Headache is Still Lurking in the Shadows.
    Martelletti P; Curto M
    Pain Ther; 2021 Dec; 10(2):777-781. PubMed ID: 34091819
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protective Effects of PACAP in Peripheral Organs.
    Toth D; Szabo E; Tamas A; Juhasz T; Horvath G; Fabian E; Opper B; Szabo D; Maugeri G; D'Amico AG; D'Agata V; Vicena V; Reglodi D
    Front Endocrinol (Lausanne); 2020; 11():377. PubMed ID: 32765418
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of pituitary adenylate cyclase-activating polypeptide on facial nerve recovery in the Guinea pig.
    Kimura H; Kawatani M; Ito E; Ishikawa K
    Laryngoscope; 2003 Jun; 113(6):1000-6. PubMed ID: 12782812
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distribution of pituitary adenylate cyclase-activating polypeptide and pituitary adenylate cyclase-activating polypeptide type I receptor mRNA in the chicken brain.
    Peeters K; Gerets HH; Arckens L; Vandesande F
    J Comp Neurol; 2000 Jul; 423(1):66-82. PubMed ID: 10861537
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Pituitary adenylate cyclase-activating polypeptide].
    Gonzalez BJ; Basille M; Vaudry D; Fournier A; Vaudry H
    Ann Endocrinol (Paris); 1998 Dec; 59(5):364-405. PubMed ID: 9949891
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.
    Vaudry D; Gonzalez BJ; Basille M; Yon L; Fournier A; Vaudry H
    Pharmacol Rev; 2000 Jun; 52(2):269-324. PubMed ID: 10835102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pituitary adenylate-cyclase-activating polypeptide (PACAP): another novel target for treatment of primary headaches?
    Ashina M; Martelletti P
    J Headache Pain; 2018 May; 19(1):33. PubMed ID: 29740710
    [No Abstract]   [Full Text] [Related]  

  • 58. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
    Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
    Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.